Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Multiscale recordings reveal the dynamic spatial structure of human seizures.

Schevon CA, Tobochnik S, Eissa T, Merricks E, Gill B, Parrish RR, Bateman LM, McKhann GM Jr, Emerson RG, Trevelyan AJ.

Neurobiol Dis. 2019 Jul;127:303-311. doi: 10.1016/j.nbd.2019.03.015. Epub 2019 Mar 18. Review.

PMID:
30898669
2.

An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs.

Sun J, Shao W, Chen X, Merricks EP, Wimsey L, Abajas YL, Niemeyer GP, Lothrop CD, Monahan PE, Samulski RJ, Nichols TC, Li C.

Mol Ther Methods Clin Dev. 2018 Aug 4;10:257-267. doi: 10.1016/j.omtm.2018.07.011. eCollection 2018 Sep 21.

3.

Mechanical Anisotropy Assessment in Kidney Cortex Using ARFI Peak Displacement: Preclinical Validation and Pilot In Vivo Clinical Results in Kidney Allografts.

Hossain MM, Detwiler RK, Chang EH, Caughey MC, Fisher MW, Nichols TC, Merricks EP, Raymer RA, Whitford M, Bellinger DA, Wimsey LE, Gallippi CM.

IEEE Trans Ultrason Ferroelectr Freq Control. 2019 Mar;66(3):551-562. doi: 10.1109/TUFFC.2018.2865203. Epub 2018 Aug 13.

PMID:
30106723
4.

Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model.

French RA, Samelson-Jones BJ, Niemeyer GP, Lothrop CD Jr, Merricks EP, Nichols TC, Arruda VR.

Blood Adv. 2018 Mar 13;2(5):505-508. doi: 10.1182/bloodadvances.2017015313. No abstract available.

5.

Influence of diabetes on the foreign body response to nitric oxide-releasing implants.

Soto RJ, Merricks EP, Bellinger DA, Nichols TC, Schoenfisch MH.

Biomaterials. 2018 Mar;157:76-85. doi: 10.1016/j.biomaterials.2017.11.044. Epub 2017 Nov 30.

6.

Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models.

Markusic DM, Nichols TC, Merricks EP, Palaschak B, Zolotukhin I, Marsic D, Zolotukhin S, Srivastava A, Herzog RW.

J Transl Med. 2017 May 1;15(1):94. doi: 10.1186/s12967-017-1200-1.

7.

Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test - Demonstrated in vitro and ex vivo.

Madsen DE, Nichols TC, Merricks EP, Waters EK, Wiinberg B.

PLoS One. 2017 Apr 6;12(4):e0175030. doi: 10.1371/journal.pone.0175030. eCollection 2017.

8.

An anti-αVβ3 antibody inhibits coronary artery atherosclerosis in diabetic pigs.

Maile LA, Busby WH, Xi G, Gollahan KP, Flowers W, Gafbacik N, Gafbacik S, Stewart K, Merricks EP, Nichols TC, Bellinger DA, Clemmons DR.

Atherosclerosis. 2017 Mar;258:40-50. doi: 10.1016/j.atherosclerosis.2017.01.030. Epub 2017 Jan 27.

PMID:
28189040
9.

Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce.

Herzog RW, Nichols TC, Su J, Zhang B, Sherman A, Merricks EP, Raymer R, Perrin GQ, Häger M, Wiinberg B, Daniell H.

Mol Ther. 2017 Feb 1;25(2):512-522. doi: 10.1016/j.ymthe.2016.11.009.

10.

Severe Hemophilia A in a Male Old English Sheep Dog with a C→T Transition that Created a Premature Stop Codon in Factor VIII.

Lozier JN, Kloos MT, Merricks EP, Lemoine N, Whitford MH, Raymer RA, Bellinger DA, Nichols TC.

Comp Med. 2016;66(5):405-411.

11.

Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.

Siner JI, Samelson-Jones BJ, Crudele JM, French RA, Lee BJ, Zhou S, Merricks E, Raymer R, Nichols TC, Camire RM, Arruda VR.

JCI Insight. 2016 Oct 6;1(16):e89371. doi: 10.1172/jci.insight.89371.

12.

Soy Phosphatidylinositol-Containing Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domain-Deleted Recombinant Canine Factor VIII in Hemophilia A Dogs.

Shetty KA, Merricks EP, Raymer R, Rigsbee N, Nichols TC, Balu-Iyer SV.

J Pharm Sci. 2016 Aug;105(8):2459-64. doi: 10.1016/j.xphs.2016.05.023. Epub 2016 Jun 30.

13.

The ictal wavefront is the spatiotemporal source of discharges during spontaneous human seizures.

Smith EH, Liou JY, Davis TS, Merricks EM, Kellis SS, Weiss SA, Greger B, House PA, McKhann GM 2nd, Goodman RR, Emerson RG, Bateman LM, Trevelyan AJ, Schevon CA.

Nat Commun. 2016 Mar 29;7:11098. doi: 10.1038/ncomms11098.

14.

Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII.

Marcos-Contreras OA, Smith SM, Bellinger DA, Raymer RA, Merricks E, Faella A, Pavani G, Zhou S, Nichols TC, High KA, Margaritis P.

Blood. 2016 Feb 4;127(5):565-71. doi: 10.1182/blood-2015-09-671420. Epub 2015 Dec 23.

15.

Experimental Validation of ARFI Surveillance of Subcutaneous Hemorrhage (ASSH) Using Calibrated Infusions in a Tissue-Mimicking Model and Dogs.

Geist RE, DuBois CH, Nichols TC, Caughey MC, Merricks EP, Raymer R, Gallippi CM.

Ultrason Imaging. 2016 Sep;38(5):346-58. doi: 10.1177/0161734615617940. Epub 2015 Nov 27.

16.

Single unit action potentials in humans and the effect of seizure activity.

Merricks EM, Smith EH, McKhann GM, Goodman RR, Bateman LM, Emerson RG, Schevon CA, Trevelyan AJ.

Brain. 2015 Oct;138(Pt 10):2891-906. doi: 10.1093/brain/awv208. Epub 2015 Jul 17.

17.

Oxidized LDL and Fructosamine Associated with Severity of Coronary Artery Atherosclerosis in Insulin Resistant Pigs Fed a High Fat/High NaCl Diet.

Nichols TC, Merricks EP, Bellinger DA, Raymer RA, Yu J, Lam D, Koch GG, Busby WH Jr, Clemmons DR.

PLoS One. 2015 Jul 6;10(7):e0132302. doi: 10.1371/journal.pone.0132302. eCollection 2015.

18.

The role of inhibition in epileptic networks.

Trevelyan AJ, Muldoon SF, Merricks EM, Racca C, Staley KJ.

J Clin Neurophysiol. 2015 Jun;32(3):227-34. doi: 10.1097/WNP.0000000000000160. Review.

PMID:
26035675
19.

The contribution of raised intraneuronal chloride to epileptic network activity.

Alfonsa H, Merricks EM, Codadu NK, Cunningham MO, Deisseroth K, Racca C, Trevelyan AJ.

J Neurosci. 2015 May 20;35(20):7715-26. doi: 10.1523/JNEUROSCI.4105-14.2015.

20.

Procoagulant microparticles in dogs with immune-mediated hemolytic anemia.

Kidd L, Geddings J, Hisada Y, Sueda M, Concannon T, Nichols T, Merricks E, Mackman N.

J Vet Intern Med. 2015 May-Jun;29(3):908-16. doi: 10.1111/jvim.12583. Epub 2015 Apr 13.

21.

Liver-directed lentiviral gene therapy in a dog model of hemophilia B.

Cantore A, Ranzani M, Bartholomae CC, Volpin M, Valle PD, Sanvito F, Sergi LS, Gallina P, Benedicenti F, Bellinger D, Raymer R, Merricks E, Bellintani F, Martin S, Doglioni C, D'Angelo A, VandenDriessche T, Chuah MK, Schmidt M, Nichols T, Montini E, Naldini L.

Sci Transl Med. 2015 Mar 4;7(277):277ra28. doi: 10.1126/scitranslmed.aaa1405.

22.

Targeted disruption of LDLR causes hypercholesterolemia and atherosclerosis in Yucatan miniature pigs.

Davis BT, Wang XJ, Rohret JA, Struzynski JT, Merricks EP, Bellinger DA, Rohret FA, Nichols TC, Rogers CS.

PLoS One. 2014 Apr 1;9(4):e93457. doi: 10.1371/journal.pone.0093457. eCollection 2014.

23.

Portal vein delivery of viral vectors for gene therapy for hemophilia.

Sherman A, Schlachterman A, Cooper M, Merricks EP, Raymer RA, Bellinger DA, Herzog RW, Nichols TC.

Methods Mol Biol. 2014;1114:413-26. doi: 10.1007/978-1-62703-761-7_27.

24.

Acoustic radiation force beam sequence performance for detection and material characterization of atherosclerotic plaques: preclinical, ex vivo results.

Behler RH, Czernuszewicz TJ, Wu CD, Nichols TC, Zhu H, Homeister JW, Merricks EP, Gallippi CM.

IEEE Trans Ultrason Ferroelectr Freq Control. 2013 Dec;60(12):2471-87. doi: 10.1109/TUFFC.2013.2847.

25.

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A.

Du LM, Nurden P, Nurden AT, Nichols TC, Bellinger DA, Jensen ES, Haberichter SL, Merricks E, Raymer RA, Fang J, Koukouritaki SB, Jacobi PM, Hawkins TB, Cornetta K, Shi Q, Wilcox DA.

Nat Commun. 2013;4:2773. doi: 10.1038/ncomms3773.

26.

Contrast-enhanced imaging of SPIO-labeled platelets using magnetomotive ultrasound.

Pope AG, Wu G, McWhorter FY, Merricks EP, Nichols TC, Czernuszewicz TJ, Gallippi CM, Oldenburg AL.

Phys Med Biol. 2013 Oct 21;58(20):7277-90. doi: 10.1088/0031-9155/58/20/7277. Epub 2013 Sep 27.

27.

Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A.

Ragni MV, Novelli EM, Murshed A, Merricks EP, Kloos MT, Nichols TC.

Thromb Haemost. 2013 Feb;109(2):248-54. doi: 10.1160/TH12-06-0447. Epub 2012 Dec 13.

28.

The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.

Finn JD, Nichols TC, Svoronos N, Merricks EP, Bellenger DA, Zhou S, Simioni P, High KA, Arruda VR.

Blood. 2012 Nov 29;120(23):4521-3. doi: 10.1182/blood-2012-06-440123. Epub 2012 Aug 23.

29.

Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.

Agersø H, Stennicke HR, Pelzer H, Olsen EN, Merricks EP, Defriess NA, Nichols TC, Ezban M.

Haemophilia. 2012 Nov;18(6):941-7. doi: 10.1111/j.1365-2516.2012.02896.x. Epub 2012 Jul 20.

30.

Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.

Nolte MW, Nichols TC, Mueller-Cohrs J, Merricks EP, Pragst I, Zollner S, Dickneite G.

J Thromb Haemost. 2012 Aug;10(8):1591-9. doi: 10.1111/j.1538-7836.2012.04826.x.

31.
32.

Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.

Dumont JA, Liu T, Low SC, Zhang X, Kamphaus G, Sakorafas P, Fraley C, Drager D, Reidy T, McCue J, Franck HW, Merricks EP, Nichols TC, Bitonti AJ, Pierce GF, Jiang H.

Blood. 2012 Mar 29;119(13):3024-30. doi: 10.1182/blood-2011-08-367813. Epub 2012 Jan 13.

33.

Animal models of hemophilia.

Sabatino DE, Nichols TC, Merricks E, Bellinger DA, Herzog RW, Monahan PE.

Prog Mol Biol Transl Sci. 2012;105:151-209. doi: 10.1016/B978-0-12-394596-9.00006-8. Review.

34.

ARFI ultrasound monitoring of hemorrhage and hemostasis in vivo in canine von Willebrand disease and hemophilia.

Scola MR, Nichols TC, Zhu H, Caughey MC, Merricks EP, Raymer RA, Margaritis P, High KA, Gallippi CM.

Ultrasound Med Biol. 2011 Dec;37(12):2126-32. doi: 10.1016/j.ultrasmedbio.2011.09.006. Epub 2011 Oct 26.

35.

Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia.

Ragni MV, Jankowitz RC, Jaworski K, Merricks EP, Kloos MT, Nichols TC.

Thromb Haemost. 2011 Oct;106(4):641-5. doi: 10.1160/TH11-04-0274. Epub 2011 Aug 11.

36.

Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs.

Karpf DM, Kjalke M, Thim L, Agersø H, Merricks EP, Defriess N, Nichols TC, Ezban M.

Haemophilia. 2011 Sep;17(5):e963-8. doi: 10.1111/j.1365-2516.2011.02580.x. Epub 2011 Jun 20.

37.

Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.

Sabatino DE, Lange AM, Altynova ES, Sarkar R, Zhou S, Merricks EP, Franck HG, Nichols TC, Arruda VR, Kazazian HH Jr.

Mol Ther. 2011 Mar;19(3):442-9. doi: 10.1038/mt.2010.240. Epub 2010 Nov 16.

38.

Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.

Finn JD, Ozelo MC, Sabatino DE, Franck HW, Merricks EP, Crudele JM, Zhou S, Kazazian HH, Lillicrap D, Nichols TC, Arruda VR.

Blood. 2010 Dec 23;116(26):5842-8. doi: 10.1182/blood-2010-06-288001. Epub 2010 Sep 28.

39.

Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B.

Hausl MA, Zhang W, Müther N, Rauschhuber C, Franck HG, Merricks EP, Nichols TC, Kay MA, Ehrhardt A.

Mol Ther. 2010 Nov;18(11):1896-906. doi: 10.1038/mt.2010.169. Epub 2010 Aug 17.

40.

Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B.

Nichols TC, Raymer RA, Franck HW, Merricks EP, Bellinger DA, DeFriess N, Margaritis P, Arruda VR, Kay MA, High KA.

Haemophilia. 2010 May;16 Suppl 3:19-23. doi: 10.1111/j.1365-2516.2010.02255.x. Review.

41.

A monoclonal antibody against alphaVbeta3 integrin inhibits development of atherosclerotic lesions in diabetic pigs.

Maile LA, Busby WH, Nichols TC, Bellinger DA, Merricks EP, Rowland M, Veluvolu U, Clemmons DR.

Sci Transl Med. 2010 Feb 10;2(18):18ra11. doi: 10.1126/scitranslmed.3000476.

42.

Prolonged activity of factor IX as a monomeric Fc fusion protein.

Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV, Lu Q, Zarbis-Papastoitsis G, Reidy TJ, Merricks EP, Nichols TC, Bitonti AJ.

Blood. 2010 Mar 11;115(10):2057-64. doi: 10.1182/blood-2009-08-239665. Epub 2010 Jan 7.

43.

Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies.

Nichols TC, Bellinger DA, Merricks EP, Raymer RA, Kloos MT, Defriess N, Ragni MV, Griggs TR.

Thrombosis. 2010;2010:461238. doi: 10.1155/2010/461238. Epub 2011 Feb 7.

44.

Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model.

Sabatino DE, Freguia CF, Toso R, Santos A, Merricks EP, Kazazian HH Jr, Nichols TC, Camire RM, Arruda VR.

Blood. 2009 Nov 12;114(20):4562-5. doi: 10.1182/blood-2009-05-220327. Epub 2009 Sep 21.

45.

Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Nichols TC, Dillow AM, Franck HW, Merricks EP, Raymer RA, Bellinger DA, Arruda VR, High KA.

ILAR J. 2009;50(2):144-67. Review.

46.

Successful treatment of canine hemophilia by continuous expression of canine FVIIa.

Margaritis P, Roy E, Aljamali MN, Downey HD, Giger U, Zhou S, Merricks E, Dillow A, Ezban M, Nichols TC, High KA.

Blood. 2009 Apr 16;113(16):3682-9. doi: 10.1182/blood-2008-07-168377. Epub 2008 Dec 23.

47.

ARFI imaging for noninvasive material characterization of atherosclerosis. Part II: toward in vivo characterization.

Behler RH, Nichols TC, Zhu H, Merricks EP, Gallippi CM.

Ultrasound Med Biol. 2009 Feb;35(2):278-95. doi: 10.1016/j.ultrasmedbio.2008.08.015. Epub 2008 Nov 21.

48.

A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease.

Ragni MV, Jankowitz RC, Chapman HL, Merricks EP, Kloos MT, Dillow AM, Nichols TC.

Haemophilia. 2008 Sep;14(5):968-77. doi: 10.1111/j.1365-2516.2008.01827.x. Epub 2008 Aug 1.

49.

Non-classical processes in surface hemostasis: mechanisms for the poly-N-acetyl glucosamine-induced alteration of red blood cell morphology and surface prothrombogenicity.

Fischer TH, Valeri CR, Smith CJ, Scull CM, Merricks EP, Nichols TC, Demcheva M, Vournakis JN.

Biomed Mater. 2008 Mar;3(1):015009. doi: 10.1088/1748-6041/3/1/015009. Epub 2008 Feb 6.

PMID:
18458496
50.

Protease-resistant insulin-like growth factor (IGF)-binding protein-4 inhibits IGF-I actions and neointimal expansion in a porcine model of neointimal hyperplasia.

Nichols TC, Busby WH Jr, Merricks E, Sipos J, Rowland M, Sitko K, Clemmons DR.

Endocrinology. 2007 Oct;148(10):5002-10. Epub 2007 Jul 19.

PMID:
17640990

Supplemental Content

Loading ...
Support Center